Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Aehr Reported Prelim Q3 Revenue of $7.6M Vs $14.32M Est, Adj EPS Loss of $(0.03)-$(0.04) Vs $0.13 Est, FY24 Revenue of $65M Vs $77.41M Est, Adj EPS of $0.48 Vs $0.77 Est

Author: Benzinga Newsdesk | March 25, 2024 07:46am

For the fiscal third quarter ended February 29, 2024, Aehr expects:

  • Revenue of approximately $7.6 million
  • GAAP net loss of approximately $1.5 million to $1.8 million, or $0.05 to $0.06 per diluted share
  • Non-GAAP net loss of approximately $0.9 million to $1.2 million, or $0.03 to $0.04 per diluted share, which excludes the impact of stock-based compensation
  • Bookings of $24.5 million
  • Backlog as of February 29, 2024, of $20 million

For the fiscal 2024 full year ending May 31, 2024, Aehr expects:

  • Total revenue of at least $65 million
  • GAAP net income of approximately $11 million or more, or $0.38 per diluted share
  • Non-GAAP net income of approximately $14 million or more, or $0.48 per diluted share, which excludes the impact of stock-based compensation

Posted In: AEHR

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist